Quantoom Biosciences, based in Nivelles, Belgium (legal entity Phoenix Biosciences SA), is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox has three steps: Ncode for AI-driven RNA sequence design, Ntensify for automated, construct-agnostic RNA production, and Ncapsulate for lipid-like calixarene nanoparticle (CNP) formulation, which the company says reduces reliance on heavily patented ionizable lipids.

Quantoom was introduced in June 2021 as an affiliate of Univercells S.A. It commercially launched Ntensify in 2023 and sells RNA production systems (mano, micro, mini and midi) to research and manufacturing customers. Its website cites 28 RNA production systems sold worldwide and 45+ clients in 27 countries, while its About page cites 25 installed Ntensify systems and five ongoing R&D collaborations.

The company targets infectious diseases, animal health and personalized oncology. Announced partners include Bio-Manguinhos/Fiocruz in Brazil, Memorial Sloan Kettering Cancer Center, TriLink BioTechnologies (CleanCap capping license), Bio Farma in Indonesia, and distributors in Europe, North America, Asia and India.